Production (Stage)
Seres Therapeutics, Inc.
MCRB
$7.05
-$0.18-2.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 3.53M | 5.13M | 2.96M | 17.88M | -- |
| Gross Profit | -3.53M | -5.13M | -2.96M | -17.88M | -- |
| SG&A Expenses | 11.89M | 12.46M | 12.71M | 16.06M | 14.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -2.59M | -- |
| Total Operating Expenses | 27.24M | 28.84M | 29.17M | 31.35M | 34.44M |
| Operating Income | -27.24M | -28.84M | -29.17M | -31.35M | -34.44M |
| Income Before Tax | 32.68M | -15.64M | -51.04M | -32.87M | -32.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.68M | -15.64M | -51.04M | -32.87M | -32.90M |
| Earnings from Discontinued Operations | -- | 0.00 | 139.81M | -- | -7.23M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.68M | -15.64M | 88.78M | -32.87M | -40.13M |
| EBIT | -27.24M | -28.84M | -29.17M | -31.35M | -34.44M |
| EBITDA | -26.16M | -27.75M | -27.77M | -29.93M | -32.88M |
| EPS Basic | 3.76 | -1.83 | 11.63 | -4.34 | -5.49 |
| Normalized Basic EPS | -1.40 | 0.15 | -4.18 | -2.71 | -2.82 |
| EPS Diluted | 3.75 | -1.89 | 11.63 | -4.40 | -5.49 |
| Normalized Diluted EPS | -1.40 | 0.15 | -4.18 | -2.71 | -2.82 |
| Average Basic Shares Outstanding | 8.70M | 8.57M | 7.63M | 7.58M | 7.31M |
| Average Diluted Shares Outstanding | 8.71M | 8.57M | 7.63M | 7.58M | 7.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |